华东医药(000963) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥8,896,632,277.36, representing a 3.47% increase compared to ¥8,598,069,911.29 in the same period last year[3]. - Net profit attributable to shareholders was ¥758,380,756.56, a decrease of 33.90% from ¥1,147,278,457.64 in the previous year[3]. - The net profit after deducting non-recurring gains and losses was ¥695,792,411.78, down 18.80% from ¥856,930,262.10 year-on-year[3]. - The company achieved operating revenue of 8.897 billion yuan in Q1 2021, a year-on-year increase of 3.47%[17]. - Net profit attributable to shareholders decreased by 33.9% to 758 million yuan, while the net profit excluding non-recurring gains and losses fell by 18.80% to 696 million yuan[17]. - Net profit decreased by 32.85% to ¥774,473,984.45, attributed to lower gross profit from subsidiaries affected by policy changes[10]. Cash Flow and Assets - The net cash flow from operating activities increased by 38.18% to ¥302,314,164.48, compared to ¥218,779,623.89 in the same period last year[3]. - Cash flow from operating activities amounted to ¥302,314,164.48, an increase from ¥218,779,623.89 in the previous period[39]. - The total assets at the end of the reporting period were ¥26,096,806,585.74, up 7.83% from ¥24,201,348,154.75 at the end of the previous year[3]. - Current assets totaled ¥16,150,855,983.21 as of March 31, 2021, compared to ¥14,655,891,702.16 at the end of 2020, indicating a rise of about 10.18%[24]. - Total liabilities reached ¥10,254,330,029.17, compared to ¥9,021,936,641.28, showing an increase of about 13.66%[26]. - Total cash and cash equivalents at the end of the period amounted to 3,083,082,210.74 CNY, down from 2,547,591,125.24 CNY in the previous year[40]. Shareholder Information - The company had a total of 168,355 common shareholders at the end of the reporting period[6]. - The largest shareholder, China Yuanda Group Co., Ltd., held 41.77% of the shares, amounting to 730,938,157 shares[6]. - The second-largest shareholder, Hangzhou East China Pharmaceutical Group Co., Ltd., held 15.69% of the shares, totaling 274,620,000 shares[6]. Investments and Acquisitions - The company invested $3 million in RAPT Therapeutics, Inc., acquiring 218,102 shares, representing 0.74% of the total shares[12]. - The company acquired 75% of Daor Biotechnology for 487.5 million yuan, becoming its controlling shareholder[20]. - The company completed the acquisition of Spanish company High Tech, marking its first overseas industry acquisition[22]. Research and Development - R&D investment in the pharmaceutical industry totaled 283 million yuan, an increase of 2.3% year-on-year[17]. - The company plans to conduct an international multi-center Phase III study for the new drug IMGN853 in Q2 2021[19]. - The company is actively preparing for the registration of multiple aesthetic medical products in China, including the Glacial®Spa and Glacial®Rx devices[22]. Financial Ratios and Metrics - The weighted average return on equity was 5.04%, down 3.85% from 8.89% in the same period last year[3]. - Basic and diluted earnings per share for the current period were both ¥0.4334, down from ¥0.6557 in the previous period[36]. - The total comprehensive income for the current period was ¥893,438,821.94, compared to ¥1,178,931,525.39 in the previous period[34]. Operational Costs - Total operating costs for Q1 2021 were ¥8,007,420,920.98, up from ¥7,564,443,071.57, reflecting a year-over-year increase of 5.85%[32]. - Sales expenses decreased to ¥1,648,517,354.06 from ¥1,911,431,524.11, a reduction of 13.73%[32]. Other Financial Information - Financial expenses decreased by 45.87% to ¥8,531,468.21, driven by increased interest income and reduced financing costs[10]. - The company reported a significant investment income of ¥6,273,981.02, compared to a loss of ¥1,132,672,992.82 in the previous period[35]. - The company experienced a decrease in financial expenses, with interest expenses at ¥15,131,329.65, down from ¥21,895,125.22 in the previous period[35].